Nigel Duffy leads the research, development, and commercialization of Sentient’s Artificial Intelligence technologies. A recognized expert in machine learning, Nigel was previously the co-founder and CTO at Numerate Inc. where he led technology development and managed the application of Numerate’s platform in collaborations with academics, biotechs, large pharmaceuticals companies, and the U.S. Government. Nigel invented Numerate’s core technologies which rapidly and repeatedly designed novel drug candidates for diseases including cancer, HCV, HIV, and heart disease. Prior to Numerate, Nigel was VP of Engineering at Pharmix and worked as a research scientist at AiLive (developer of the Wii Motion Plus), where he played a key role in applying machine learning to computer games. Nigel also spent time at Amazon A9 working on tools for large scale analytics in product search.
The author of eleven granted or pending patents, Nigel’s technology is in regular use by more than 50 million users. He has published 15 academic papers including highly cited papers on machine learning, computational biology, and linguistics. Nigel holds a Masters in Mathematics from University College Dublin in Ireland and a PhD in Computer Science (Machine Learning Theory) from the University of California at Santa Cruz.